Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sirius licenses sepsis markers to Tm Bioscience

This article was originally published in Clinica

Executive Summary

Molecular test developer Tm Bioscience has excusively licensed from fellow Canadian company Sirius Genomics specific biomarkers associated with drugs used for treating severe sepsis. Toronto-based Tm Bioscience will incorporate these markers into a test that identifies patients who would respond well to vasopressin and Xigris, the two drugs commonly used to treat the condition. The product, scheduled for launch in the second half of 2007, is expected to generate sales of over US$100m in the first three years of commercialisation.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051199

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel